GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pharma-Bio Serv Inc (OTCPK:PBSV) » Definitions » Return-on-Tangible-Asset

Pharma-Bio Serv (Pharma-Bio Serv) Return-on-Tangible-Asset : -5.54% (As of Jan. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Pharma-Bio Serv Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Pharma-Bio Serv's annualized Net Income for the quarter that ended in Jan. 2024 was $-1.08 Mil. Pharma-Bio Serv's average total tangible assets for the quarter that ended in Jan. 2024 was $19.57 Mil. Therefore, Pharma-Bio Serv's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 was -5.54%.

The historical rank and industry rank for Pharma-Bio Serv's Return-on-Tangible-Asset or its related term are showing as below:

PBSV' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -7.76   Med: 5.91   Max: 10.85
Current: 3.07

During the past 13 years, Pharma-Bio Serv's highest Return-on-Tangible-Asset was 10.85%. The lowest was -7.76%. And the median was 5.91%.

PBSV's Return-on-Tangible-Asset is ranked better than
58.11% of 666 companies
in the Healthcare Providers & Services industry
Industry Median: 1.46 vs PBSV: 3.07

Pharma-Bio Serv Return-on-Tangible-Asset Historical Data

The historical data trend for Pharma-Bio Serv's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma-Bio Serv Return-on-Tangible-Asset Chart

Pharma-Bio Serv Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.03 7.25 -7.76 4.52 6.46

Pharma-Bio Serv Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.20 8.00 10.54 -0.94 -5.54

Competitive Comparison of Pharma-Bio Serv's Return-on-Tangible-Asset

For the Health Information Services subindustry, Pharma-Bio Serv's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma-Bio Serv's Return-on-Tangible-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Pharma-Bio Serv's Return-on-Tangible-Asset falls into.



Pharma-Bio Serv Return-on-Tangible-Asset Calculation

Pharma-Bio Serv's annualized Return-on-Tangible-Asset for the fiscal year that ended in Oct. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Oct. 2023 )  (A: Oct. 2022 )(A: Oct. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Oct. 2023 )  (A: Oct. 2022 )(A: Oct. 2023 )
=1.31/( (20.651+19.902)/ 2 )
=1.31/20.2765
=6.46 %

Pharma-Bio Serv's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=-1.084/( (19.902+19.231)/ 2 )
=-1.084/19.5665
=-5.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2024) net income data.


Pharma-Bio Serv  (OTCPK:PBSV) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Pharma-Bio Serv Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Pharma-Bio Serv's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma-Bio Serv (Pharma-Bio Serv) Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Road 696, Pharma-Bio Serv Building, Dorado, PRI, 00646
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies.
Executives
Elizabeth Plaza 10 percent owner 363 DORADO BEACH EAST, DORADO PR 00646
Altura Victor Sanchez officer: President and CEO C/O PHARMA-BIO SERV, INC., 6 ROAD 696, DORADO PR 00646
San Juan Holdings 10 percent owner 255 PONCE DE LEON, SUITE 305 MCS PLAZA, SAN JUAN PR 00917
Pedro J Lasanta officer: Chief Financial Officer 373 MENDEZ VIGO, STE 110, DORADO PR 00646
Dov Perlysky director 2 LAKESIDE DRIVE WEST, LAWRENCE NY 11559
L P Venturetek 10 percent owner C/O DAVID SELENGUT ELLENOFF GROSSMAN, 370 LEXINGTON AVENUE 19TH FLOOR, NEW YORK NY 10017
Barron Partners Lp 10 percent owner 730 FIFTH AVENUE, 25TH FLOOR, NEW YORK NY 10019
Manuel O Morera officer: Chief Financial Officer 373 MENDEZ VIGO, SUITE 110, DORADO PR 00646
Mark A Fazio officer: Exec. Vice President and COO P O BOX 1026 GREEN STREET, PERKASIE PA 18944
Kirk Wheeler Michel director 209 EAST TRYON STREET, HILLSBOROUGH NC 27278
Irving L Wiesen director 1273 NORTH AVENUE, APT 1E 7, NEW ROCHELLE NY 10804
Howard Spindel director 39 BROADWAY SUITE 3300, NEW YORK NY 10028
Nelida Plaza Rodriguez officer: Vice President and Secretary G11 CALLE MADRE PERLA URB, DORADO DEL MAR, DORADO PR 00646
Krovim Llc director, 10 percent owner, officer: Manager P.O. BOX 339, LAWRENCE NY 11559